An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

NCT02319460 · clinicaltrials.gov ↗

COMPLETED

Status

2238

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemorrhage

Interventions

BIOLOGICAL: Kcentra®
BIOLOGICAL: Plasma

Sponsor

CSL Behring

Collaborators

[object Object]